Format

Send to

Choose Destination
J Glob Antimicrob Resist. 2019 Jan 22. pii: S2213-7165(19)30021-9. doi: 10.1016/j.jgar.2019.01.014. [Epub ahead of print]

First report of the new emerging global clone ST1193 among clinical isolates of extended-spectrum ß-lactamase (ESBL)-producing Escherichia coli from Germany.

Author information

1
Bavarian Health and Food Safety Authority, Erlangen, Germany; Mikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany. Electronic address: giuseppe.valenza@lgl.bayern.de.
2
Mikrobiologisches Institut - Klinische Mikrobiologie, Immunologie und Hygiene, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Erlangen, Germany.
3
Bavarian Health and Food Safety Authority, Erlangen, Germany.
4
Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.

Abstract

OBJECTIVES:

Sequence type 1193 (ST1193) is a new emerging global clone of Escherichia coli. Main goal of this study was to determine the prevalence and the molecular characteristics of ST1193 among clinical isolates of extended-spectrum ß-lactamase (ESBL)-producing E. coli from the University Hospital of Erlangen, Germany.

METHODS:

Between November 2015 and February 2016, all consecutive non-replicate clinical isolates of E. coli showing resistance to cefotaxime or ceftazidime were further analyzed for ESBL-production by combined disc method. ESBL genes were identified by PCR and sequencing. Bacterial strain typing was performed by PCR-based phylogrouping, multilocus sequence typing (MLST) and whole-genome sequencing (WGS).

RESULTS:

ESBL-production was confirmed in 51 isolates. The globally dominant ST131 occurred with a frequency of 37.2% (n=19). Major non-ST131 sequence types were ST38 (n=4; 7.8%), ST10 (n=3; 5.9%) and ST1193 (n=3; 5.9%). Among the ESBL-producing E. coli ST1193, two expressed the ESBL-type CTX-M-14 and one the ESBL-type CTX-M-15. All of them belonged to the serogroup O75:H5 and phylogroup B2, harbored the plasmids IncFIA and IncFIB and the virulence factors genes iha, sat, gad, vat and senB. Moreover, they showed a ciprofloxacin resistance and exhibited a set of 4 conserved mutations defining quinolone-resistance (gyrA S83L, gyrA D87N, parC S80I and parC L416F).

CONCLUSIONS:

This study revealed for the first time in Germany the occurrence of ST1193 among clinical isolates of ESBL-producing E. coli. Further national or regional multicenter studies are needed to assess the effective relevance of ESBL-producing E. coli ST1193 as nosocomial pathogens in Germany.

KEYWORDS:

ESBL; Epidemiology; Escherichia coli; Infections; ST1193; ST131

PMID:
30682563
DOI:
10.1016/j.jgar.2019.01.014

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center